- Home
- GSIW vs DYAI Comparison
GSIW vs DYAI Comparison
Compare GSIW & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- DYAI
- Stock Information
- Founded
- GSIW 2016
- DYAI 1979
- Country
- GSIW Hong Kong
- DYAI United States
- Employees
- GSIW N/A
- DYAI N/A
- Industry
- GSIW
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GSIW
- DYAI Health Care
- Exchange
- GSIW Nasdaq
- DYAI Nasdaq
- Market Cap
- GSIW 27.2M
- DYAI 28.3M
- IPO Year
- GSIW 2023
- DYAI 2004
- Fundamental
- Price
- GSIW $1.75
- DYAI $1.00
- Analyst Decision
- GSIW
- DYAI Strong Buy
- Analyst Count
- GSIW 0
- DYAI 1
- Target Price
- GSIW N/A
- DYAI $6.00
- AVG Volume (30 Days)
- GSIW 2.6M
- DYAI 63.2K
- Earning Date
- GSIW 01-01-0001
- DYAI 08-12-2025
- Dividend Yield
- GSIW N/A
- DYAI N/A
- EPS Growth
- GSIW N/A
- DYAI N/A
- EPS
- GSIW N/A
- DYAI N/A
- Revenue
- GSIW $1,313,795.00
- DYAI $3,554,344.00
- Revenue This Year
- GSIW N/A
- DYAI $22.56
- Revenue Next Year
- GSIW N/A
- DYAI $30.95
- P/E Ratio
- GSIW N/A
- DYAI N/A
- Revenue Growth
- GSIW N/A
- DYAI 57.59
- 52 Week Low
- GSIW $0.35
- DYAI $0.91
- 52 Week High
- GSIW $12.30
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- GSIW 72.13
- DYAI 46.85
- Support Level
- GSIW $1.26
- DYAI $0.91
- Resistance Level
- GSIW $1.66
- DYAI $1.02
- Average True Range (ATR)
- GSIW 0.14
- DYAI 0.05
- MACD
- GSIW -0.02
- DYAI 0.01
- Stochastic Oscillator
- GSIW 92.25
- DYAI 35.07
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.